Literature DB >> 9420221

A lymph node-derived cytopathic simian immunodeficiency virus Mne variant replicates in nonstimulated peripheral blood mononuclear cells.

J T Kimata1, A Mozaffarian, J Overbaugh.   

Abstract

Lymph nodes (LNs) are sites of active human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) replication and disease at both early and late stages of infection. Consequently, variant viruses that replicate efficiently and subsequently cause immune dysfunction may be harbored in this tissue. To determine whether LN-associated SIVs have an increased capacity to replicate and induce cytopathology, a molecular clone of SIV was isolated directly from DNA extracted from unpassaged LN tissue of a pig-tailed macaque (Macaca nemestrina) infected with SIVMne. The animal had declining CD4+ T-lymphocyte counts at the time of the LN biopsy. In human CD4+ T-cell lines, the LN-derived virus, SIVMne027, replicated with relatively slow kinetics and was minimally cytopathic and non-syncytium inducing compared to other SIVMne clones. However, in phytohemagglutinin-stimulated pig-tailed macaque peripheral blood mononuclear cells (PBMCs), SIVMne027 replicated efficiently and was highly cytopathic for the CD4+ T-cell population. Interestingly, unlike other SIVMne clones, SIVMne027 also replicated to a high level in nonstimulated macaque PBMCs. High-level replication depended on the presence of both the T-cell and monocyte/macrophage populations and could be enhanced by interleukin-2 (IL-2). Finally, the primary determinant governing the ability of SIVMne027 to replicate in nonstimulated and IL-2-stimulated PBMCs mapped to gag-pol-vif. Together, these data demonstrate that LNs may harbor non-syncytium-inducing, cytopathic viruses that replicate efficiently and are highly responsive to the effects of cytokines such as IL-2.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9420221      PMCID: PMC109370     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

1.  The cytopathicity of a simian immunodeficiency virus Mne variant is determined by mutations in Gag and Env.

Authors:  J T Kimata; J Overbaugh
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection.

Authors:  B Asjö; L Morfeldt-Månson; J Albert; G Biberfeld; A Karlsson; K Lidman; E M Fenyö
Journal:  Lancet       Date:  1986-09-20       Impact factor: 79.321

3.  Changes in the extracellular envelope glycoprotein of variants that evolve during the course of simian immunodeficiency virus SIVMne infection affect neutralizing antibody recognition, syncytium formation, and macrophage tropism but not replication, cytopathicity, or CCR-5 coreceptor recognition.

Authors:  L M Rudensey; J T Kimata; E M Long; B Chackerian; J Overbaugh
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

4.  Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM).

Authors:  T M Fletcher; B Brichacek; N Sharova; M A Newman; G Stivahtis; P M Sharp; M Emerman; B H Hahn; M Stevenson
Journal:  EMBO J       Date:  1996-11-15       Impact factor: 11.598

5.  The U3 promoter region of the acutely lethal simian immunodeficiency virus clone smmPBj1.9 confers related biological activity on the apathogenic clone agm3mc.

Authors:  M T Dittmar; K Cichutek; P N Fultz; R Kurth
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

6.  Interleukin-2 induction of T-cell G1 progression and c-myb expression.

Authors:  J B Stern; K A Smith
Journal:  Science       Date:  1986-07-11       Impact factor: 47.728

Review 7.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

8.  Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.

Authors:  M Tersmette; R E de Goede; B J Al; I N Winkel; R A Gruters; H T Cuypers; H G Huisman; F Miedema
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

9.  Inoculation of baboons and macaques with simian immunodeficiency virus/Mne, a primate lentivirus closely related to human immunodeficiency virus type 2.

Authors:  R E Benveniste; W R Morton; E A Clark; C C Tsai; H D Ochs; J M Ward; L Kuller; W B Knott; R W Hill; M J Gale
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

10.  Biologic features of HIV-1 that correlate with virulence in the host.

Authors:  C Cheng-Mayer; D Seto; M Tateno; J A Levy
Journal:  Science       Date:  1988-04-01       Impact factor: 47.728

View more
  19 in total

1.  Vif substitution enables persistent infection of pig-tailed macaques by human immunodeficiency virus type 1.

Authors:  Rajesh Thippeshappa; Patricia Polacino; Monica T Yu Kimata; Edward B Siwak; David Anderson; Weiming Wang; Laura Sherwood; Reetakshi Arora; Michael Wen; Paul Zhou; Shiu-Lok Hu; Jason T Kimata
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

Review 2.  Primate immunodeficiency virus classification and nomenclature: Review.

Authors:  Brian T Foley; Thomas Leitner; Dimitrios Paraskevis; Martine Peeters
Journal:  Infect Genet Evol       Date:  2016-10-24       Impact factor: 3.342

3.  Capture and transfer of simian immunodeficiency virus by macaque dendritic cells is enhanced by DC-SIGN.

Authors:  Monica T Yu Kimata; Marina Cella; Julia E Biggins; Colin Rorex; Robert White; Sarah Hicks; Joelle M Wilson; Parul G Patel; Jonathan S Allan; Marco Colonna; Jason T Kimata
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  Glycosyl-Phosphatidylinositol-Anchored Anti-HIV Env Single-Chain Variable Fragments Interfere with HIV-1 Env Processing and Viral Infectivity.

Authors:  Anisha Misra; Emile Gleeson; Weiming Wang; Chaobaihui Ye; Paul Zhou; Jason T Kimata
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

5.  Adaptation to the interferon-induced antiviral state by human and simian immunodeficiency viruses.

Authors:  Julia Bitzegeio; Marissa Sampias; Paul D Bieniasz; Theodora Hatziioannou
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

6.  Relative replication capacity of phenotypic SIV variants during primary infections differs with route of inoculation.

Authors:  Tasha Biesinger; Robert White; Monica T Yu Kimata; Brenda K Wilson; Jonathan S Allan; Jason T Kimata
Journal:  Retrovirology       Date:  2010-10-13       Impact factor: 4.602

7.  Coreceptor specificity of temporal variants of simian immunodeficiency virus Mne.

Authors:  J T Kimata; J J Gosink; V N KewalRamani; L M Rudensey; D R Littman; J Overbaugh
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

8.  Quantitative analysis of human immunodeficiency virus type 1 DNA dynamics by real-time PCR: integration efficiency in stimulated and unstimulated peripheral blood mononuclear cells.

Authors:  Youichi Suzuki; Naoko Misawa; Chihiro Sato; Hirotaka Ebina; Takao Masuda; Naoki Yamamoto; Yoshio Koyanagi
Journal:  Virus Genes       Date:  2003-10       Impact factor: 2.332

9.  Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy.

Authors:  Zandrea Ambrose; Sarah Palmer; Valerie F Boltz; Mary Kearney; Kay Larsen; Patricia Polacino; Leon Flanary; Kelli Oswald; Michael Piatak; Jeremy Smedley; Wei Shao; Norbert Bischofberger; Frank Maldarelli; Jason T Kimata; John W Mellors; Shiu-Lok Hu; John M Coffin; Jeffrey D Lifson; Vineet N KewalRamani
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

10.  Unique pattern of convergent envelope evolution in simian immunodeficiency virus-infected rapid progressor macaques: association with CD4-independent usage of CCR5.

Authors:  Houman Dehghani; Bridget A Puffer; Robert W Doms; Vanessa M Hirsch
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.